IR
Superintel
OverviewMarketsWatchlist
© 2026 IR SuperintelMethodologyContact

Apellis Pharmaceuticals

CUSIP: 03753UAB2 | TRACE | 54 institutional holders

Quarters

Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025
CompareDetailedHistoricalFundsOptions13D/13GPeersTargetingTrading SummaryProfile

Institutional Holders — Q1 2026

DeepCurrents Investment Group LLC44,494,000
1.5% of portfolio›$47.2M
Linden Advisors LP28,138,000
0.2% of portfolio›$29.6M
Tenor Capital Management Co., L.P.11,950,000
0.2% of portfolio›$12.7M
D. E. Shaw & Co., Inc.5,000,000
0.0% of portfolio›$5.3M
Wolverine Asset Management LLC3,122,000
0.0% of portfolio›$3.3M
Cantor Fitzgerald, L. P.1,130,000
0.0% of portfolio›$1.2M
Citigroup Inc6,000
0.0% of portfolio›$6.3K
StyleTurnoverLocationFiled
DeepCurrents Investment Group LLC
44,494,000$47.2M1.5%GARPHighNew York, NY2026-05-15
Linden Advisors LP
28,138,000$29.6M0.2%GrowthHighNew York, NY2026-05-15
Tenor Capital Management Co., L.P.
11,950,000$12.7M0.2%GARPHighNew York, NY2026-05-15
D. E. Shaw & Co., Inc.
5,000,000$5.3M0.0%GARPHighNew York, NY2026-05-15
Wolverine Asset Management LLC
3,122,000$3.3M0.0%Deep ValueVery HighChicago, IL2026-05-04
Cantor Fitzgerald, L. P.
1,130,000$1.2M0.0%Agg GrowthHighNew York, NY2026-05-15
Citigroup Inc
6,000$6.3K0.0%CoreMediumNew York, NY2026-05-11